Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | TGM2 | P21980 | 1/20 | 0.71 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.66 |
| ▸ | KRAS | P01116 | 4/20 | 0.65 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.63 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.61 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.61 |
| ▸ | HINT1 | P49773 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822597 | 0.99 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL29486374 | 0.99 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL29486372 | 0.99 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL29353975 | 0.99 | NT5E (0.71) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL18320601 | 0.95 | NT5E (0.72) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL16004523 | 0.95 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL20924563 | 0.95 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL21516016 | 0.95 | RNASEL (0.71) | TGM2RNASELP2RX3P2RY2 | |
| SCHEMBL20924417 | 0.95 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL | |
| SCHEMBL22646974 | 0.95 | NT5E (0.67) | NT5ETGM2FUT5KRASRNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066423-A1 | SESTRIN-MAPK COMPLEX INHIBITORS | SENTCELL LTD (GB) | 2025-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066423-A1 | SESTRIN-MAPK COMPLEX INHIBITORS | MAPK1, MAPKAP1, MAPK3 | NT5E 4662/4885TGM2 2975/4885FUT5 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.